Day: March 19, 2024

Louvain-la-Neuve, Belgium, March 19, 2024 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and electron beam and X-ray solutions for industrial irradiation, announced today it has signed a contract for the installation of a Be-Efficient electron beam irradiation solution equipped with two Rhodotron® accelerators in Germany. This Be-Efficient electron beam solution includes two Rhodotron® accelerators, a Beagle® production line control system and a Building Safety System. The Be-Efficient solution will be used for e-beam irradiation for polymer crosslinking applications, which enhances the resistance of polymers. The typical price for a Be-Efficient irradiation solution ranges from EUR 11 million to EUR 18 million, depending on the configuration and options. In addition to this contract,...

New York, NY & Madrid, Spain, March 19, 2024 (GLOBE NEWSWIRE) — WISe.ART to Host the Prestigious ProArte y Cultura Mayte Spínola Gold Medals 2023 at the Iconic Nasdaq Building in New York City on April 1, 2024 New York / Madrid – March 19, 2024: WISeKey International Holding Ltd. (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), a global leader in cybersecurity, digital identity, and Internet of Things (IoT) innovations, operating as a holding company, in partnership with Grupo Pro Arte y Cultura, announced that its subsidiary WISe.ART is will be hosting the Mayte Spínola Gold Medals 2023, in its special 10th Edition, at the Nasdaq MarketSite located at 4 Times Square (43rd & Broadway), in the heart of New York City, on April 1, 2024. This year’s event is particularly momentous as it celebrates the 80th anniversary of Mayte Spínola,...

OSLO, Norway, March 19, 2024 (GLOBE NEWSWIRE) — Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced key updates of the inverse vaccine platform with the potential to treat autoimmune diseases at the 7th Antigen-Specific Immune Tolerance Drug Development Summit in Boston. Nykode employs its unique technology platform to pioneer the field of inverse vaccines, with the potential to develop high-precision treatments for autoimmune diseases. At the conference, Nykode demonstrated for the first time a significant effect in a therapeutic setting in a preclinical model for Multiple Sclerosis (MS) with its inverse vaccine platform. The data also illustrate the strong contribution of the specific targeting unit and confirm that...

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss ExchangeGENEVA, Switzerland – March 18, 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that, concurrent to the decision to wind-down the company’s operations, Catarina Edfjäll, Ph.D. has decided to step down from the Board effective today. “We would like to warmly thank Catarina for her significant contribution to the company over the last years. We are grateful to have had the opportunity to work closely with her and we wish her continued success in her future endeavors,” said Ernest Loumaye, Board Chairman. About ObsEva ObsEva is a biopharmaceutical company developing novel therapies to improve women’s reproductive health and pregnancy. ObsEva has established a development program...

Partnership Revolutionizes Travel in India, Offering Travelers Convenience and Flexibility in Planning Their Journeys End to End BANGALORE, India, March 19, 2024 (GLOBE NEWSWIRE) — Zoomcar Holdings, Inc. (“Zoomcar” or the “Company”) (Nasdaq: ZCAR), the NASDAQ-listed leading marketplace for car sharing, and EaseMyTrip, one of India’s largest online travel platforms, today announced a strategic partnership to offer customers unparalleled convenience in their travel arrangements. With this partnership, Zoomcar’s wide range of self-drive cars have been seamlessly integrated into the EaseMyTrip platform, allowing users to book their preferred Zoomcar directly from the EaseMyTrip app offering travelers convenience  and flexibility in planning their journeys. EaseMyTrip users will now have access to Zoomcar’s extensive fleet...

CONSHOHOCKEN, Pa., March 18, 2024 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced the pricing of its underwritten public offering of 750,000 shares of its common stock at a public offering price of $260.0000 per share, and, to certain investors, pre-funded warrants to purchase 1,557,692 shares of common stock at a price of $259.9999 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each such pre-funded warrant. The size of the offering was increased by $100 million subsequent to the initial announcement of the offering. The gross proceeds to Madrigal from the offering, before deducting the underwriting...

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Boston, MA, March 18, 2024 (GLOBE NEWSWIRE) — MiniLuxe Holding Corp. (TSXV: MNLX) (“MiniLuxe” or the “Company”) is pleased to announce that further to its press release dated February 16, 2024, it has completed its shares for debt transaction, whereby an aggregate of 597,446 Class A subordinate voting shares were issued to Paintbox, LLC and certain arm’s length non-management employees at a price of per share of CAD$0.52, in satisfaction of an aggregate of USD$221,959 previously owing by the Company to the parties. The pricing was based on the closing price of the Company’s Class A subordinate voting shares of CAD$0.65 on February 16, 2024, the date of the Company’s application to the TSXV, discounted by 20% in accordance with TSXV...

BROOKFIELD, NEWS, March 18, 2024 (GLOBE NEWSWIRE) — Brookfield Corporation (“Brookfield”) (NYSE: BN, TSX: BN) today announced that it has filed its 2023 annual materials on Form 40-F, including its audited financial statements and management’s discussion and analysis for the year ended December 31, 2023, with the SEC on EDGAR as well as with the Canadian securities authorities on SEDAR. These documents are also available at www.brookfield.com and a hardcopy will be provided to shareholders free of charge upon request. About Brookfield Corporation Brookfield Corporation is a leading global investment firm focused on building long-term wealth for institutions and individuals around the world. We have one of the largest pools of discretionary capital globally, which is deployed across our three core businesses – asset management,...